BSR Statement on Lumiracoxib
Document Actions
The British Society for Rheumatology has been informed of the decision taken by the European Medicines Agency (EMEA) to suspend the use of lumiracoxib.
The Commission on Human Medicines (CHM) has advised that lumiracoxib is associated with a risk of severe, potentially life-threatening hepatotoxicity that appears greater than for a number of other authorised non-steroidal anti-inflammatory drugs.
The BSR strongly recommends that all patients who have been taking these drugs consult their general practitioner or rheumatologist as soon as possible with a view to finding alternative medication.
If you require further advice on the guidance please contact the Medicines and Healthcare products Regulatory Agency (MHRA) at 020 7084 2000 (www.mhra.gov.uk).
For further information contact:
Katy Lewis
klewis@rheumatology.org.uk
(020) 7842 0919
November 2007